>>> Sainsbury Made Approach to Home Retail, Offer Rejected

Sainsbury Made Approach to Home Retail, Offer Rejected

Sainsbury made approach to Home Retail in form of shares and cash in November.
* Sainsbury says combination is attractive proposition
* Has until Feb. 2 to make offer to Home Retail
* No certainty that there will be a formal offer
* Home retail share rise as much as 22%

>>> US Early premarket gappers

Early premarket gappers

Gapping up: EXEL +9.3%, HMY +5.7%, SWHC +5.5%, CTIC +4.1%, RPRX +3.8%, BIN +3.4%, HIW +3.4%, FSLR +3.4%, VCEL +2.8%, BXLT +2%, FCX +1.7%, MT +1.5%, VALE +1.3%, SLV +1.1%, GDX +1.1%, ABX +1%, GG +1%

Gapping down: AKBA -4.5%, SDRL -3.7%, SYT -2.8%, ABB -2.7%, TOT -2.7%, RIG -2.7%, STO -2.6%, XLRN -2.3%, SAN -2.3%, PHG -2.3%, ASML -2.3%, LLY -2.3%, ERIC -2.2%, UN -1.9%, SAP -1.8%, BP -1.8%, DD -1.5%, BHP -1.5%, BCS -1.5%, RDS.A -1.4%, ING -1.4%, RCL -1.4%, DB -1.3%, DIS -1.2%, AZN -1%, HSBC -0.9%, COP -0.8%

>>> Eli Lilly follow-up: LLY reaffirms 2015 guidance, issues 2016 guidance below

Eli Lilly follow-up: LLY reaffirms 2015 guidance, issues 2016 guidance below expectations
  • Co reaffirms guidance for FY15 (Dec), sees EPS of $3.40-3.45 vs. $3.44 Capital IQ Consensus Estimate.
  • Co issues downside guidance for FY16 (Dec), sees EPS of $3.45-3.55 vs. $3.64 Capital IQ Consensus Estimate; sees FY16 (Dec) revs of $20.2-20.7 bln vs. $21.33 bln Capital IQ Consensus Estimate. Non-GAAP figures for 2016 exclude amortization of intangibles as well as integration costs associated with the Novartis Animal Health acquisition.
    • Excluding the unfavorable impact of foreign exchange rates, the company expects revenue growth from a number of established products including Humalog, Trajenta, Cialis, Forteo, Strattera, Erbitux, and animal health products, as well as higher revenues from new products including Cyramza, Trulicity, Jardianc, Portrazza, and Basaglar.
  • "In 2016 we expect multiple regulatory actions across therapeutic areas including diabetes, oncology and immunology," said Derica Rice, Lilly's executive vice president for global services and chief financial officer.

>>> Volkswagen faces up to $80 billion in penalties in US Justice Department law

Nothing really new just some precisions

Volkswagen faces up to $80 billion in penalties in US Justice Department lawsuit

In its 30-page complaint, the Justice Department said the charges carry fines of between $2,750 and $37,500 per car, per violation. Based on four separate violations laid out in the complaint, VW could theoretically face as much as $80 billion in penalties, which is higher than the $18 billion estimated when the scandal broke in September.

>>> US Chemical - Citi - Few Reco Changes

*AIR PRODUCTS CUT TO NEUTRAL VS BUY AT CITI, PT $143
*DUPONT CUT TO NEUTRAL VS BUY AT CITI, PT $70
*AGRIUM RAISED TO NEUTRAL VS SELL AT CITI, PT $91
*CELANESE RAISED TO BUY VS NEUTRAL AT CITI, PT $77
*EASTMAN CHEMICAL RAISED TO BUY VS NEUTRAL AT CITI, PT $75